Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart’s Top Stock Pick. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Clovis Oncology Inc (CLVS)

Clovis Oncology Inc (CLVS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 11,770
  • Shares Outstanding, K 144,955
  • Annual Sales, $ 148,760 K
  • Annual Income, $ -264,520 K
  • 60-Month Beta 0.24
  • Price/Sales 0.08
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade CLVS with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -1.75
  • Most Recent Earnings -0.39 on 11/09/22
  • Next Earnings Date N/A
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Options Overview Details

View History
  • Implied Volatility 0.00% ( unch)
  • Historical Volatility 393.04%
  • IV Percentile 0%
  • IV Rank N/A
  • IV High 0.00% on N/A
  • IV Low 0.00% on N/A
  • Put/Call Vol Ratio N/A
  • Today's Volume N/A
  • Volume Avg (30-Day) N/A
  • Put/Call OI Ratio N/A
  • Today's Open Interest N/A
  • Open Int (30-Day) N/A

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.0760 +6.84%
on 12/16/22
0.3772 -78.47%
on 12/01/22
-0.2679 (-76.74%)
since 11/18/22
3-Month
0.0760 +6.84%
on 12/16/22
1.3100 -93.80%
on 10/04/22
-1.0388 (-92.75%)
since 09/20/22
52-Week
0.0760 +6.84%
on 12/16/22
3.3200 -97.55%
on 12/21/21
-3.1288 (-97.47%)
since 12/20/21

Most Recent Stories

More News
Zacks.com featured highlights include Clovis Oncology, NiSource, DocuSign, Root and Endava

Clovis Oncology, NiSource, DocuSign, Root and Endava are part of the Zacks Screen of the Week article.

NI : 26.93 (-1.25%)
CLVS : 0.0812 (-5.58%)
DOCU : 63.66 (+1.13%)
DAVA : 90.48 (-0.92%)
ROOT : 6.57 (-6.48%)
Bet on 5 Top Stocks With Rising P/E

Forget undervalued stocks, play top-ranked stocks like Clovis Oncology (CLVS), NiSource (NI), DocuSign (DOCU), Root (ROOT) and Endava (DAVA).

NI : 26.93 (-1.25%)
CLVS : 0.0812 (-5.58%)
DOCU : 63.66 (+1.13%)
DAVA : 90.48 (-0.92%)
ROOT : 6.57 (-6.48%)
Clovis (CLVS) Files for Bankruptcy Amid Lack of Financial Aid

Recent regulatory developments force Clovis (CLVS) to file for bankruptcy. The company inks a stalking horse agreement with Novartis for one of its pipeline candidates.

AZN : 63.72 (+0.31%)
NVS : 86.07 (+0.70%)
MRK : 104.48 (+0.43%)
CLVS : 0.0812 (-5.58%)
Clovis Oncology Files for Chapter 11 Protection and Enters into Agreement to Sell FAP-2286

Clovis Oncology, Inc. (NASDAQ:CLVS) (“Clovis” or the Company”), a biopharmaceutical company focused on acquiring, developing, and commercializing innovative anti-cancer agents in the U.S., Europe,...

CLVS : 0.0812 (-5.58%)
Clovis (CLVS) Down 18.1% Since Last Earnings Report: Can It Rebound?

Clovis (CLVS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

CLVS : 0.0812 (-5.58%)
ALNY : 216.66 (-3.34%)
Pre-Market Brief: Stocks Mixed As Labor Market Strength Weigh On Sentiment

December S&P 500 futures (ESZ22) are trending down -0.30% this morning after three major US benchmark indices closed mixed on Friday as the November payrolls report fueled expectations the Federal Reserve...

ESZ22 : 3,871.47s (-0.66%)
TXMD : 5.17 (+0.25%)
IOVA : 8.02 (-2.20%)
IMPP : 0.2431 (-2.76%)
CLVS : 0.0812 (-5.58%)
UTHR : 251.71 (-1.38%)
SBUX : 105.60 (+0.55%)
Clovis (CLVS) Stock Down 50% in the Past 6 Months: Here's Why

Clovis Oncology (CLVS) tanks in the past six months following the possibility of a bankruptcy filing in the near term.

AZN : 63.72 (+0.31%)
MRK : 104.48 (+0.43%)
ANGN : 0.7000 (+1.45%)
CLVS : 0.0812 (-5.58%)
Down 67.7% in 4 Weeks, Here's Why You Should You Buy the Dip in Clovis (CLVS)

Clovis (CLVS) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings...

CLVS : 0.0812 (-5.58%)
Clovis (CLVS) Plummets on News of Possible Bankruptcy Filing

Clovis (CLVS) tanks following the possibility of a bankruptcy filing in the near term after recent regulatory developments impacted current revenues and the commercial potential of Rubraca.

PFE : 43.33 (-0.98%)
CLVS : 0.0812 (-5.58%)
PBYI : 4.67 (+3.32%)
SNDX : 26.25 (-1.06%)
Clovis Oncology (CLVS) Reports Q3 Loss, Lags Revenue Estimates

Clovis (CLVS) delivered earnings and revenue surprises of 7.14% and 11.87%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

CLVS : 0.0812 (-5.58%)
INVO : 0.6100 (-3.17%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Business Summary

Clovis Oncology, Inc. is a biopharmaceutical companyfocused on acquiring, developing and commercializing innovative anti-cancer agents.'Clovis has only one marketed drug in its portfolio a poly ADP-ribose polymerase inhibitor, namely Rubraca that is approved for the treatment of certain patients with...

See More

Key Turning Points

3rd Resistance Point 0.1148
2nd Resistance Point 0.1063
1st Resistance Point 0.0937
Last Price 0.0812
1st Support Level 0.0726
2nd Support Level 0.0641
3rd Support Level 0.0515

See More

52-Week High 3.3200
Fibonacci 61.8% 2.0808
Fibonacci 50% 1.6980
Fibonacci 38.2% 1.3152
Last Price 0.0812
52-Week Low 0.0760

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar